drugset / Trial / NCT00457925

Absorption, Distribution, Metabolism And Excretion Study For GSK221149A

NCT00457925 ↗

Phase 1 Completed 6 enrolled GlaxoSmithKline
RandomizedSingle-groupOpen-labelTreatment

Summary

This is a phase one study investigating the absorption, distribution, metabolism and excretion of GSK221149A in six healthy women of non-child bearing potential.

Timeline

Start
2006-10
Primary completion
—
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Retosiban Small molecule — Oral

Indications